Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ira Berger

Internal Medicine Rockville, MD Medical Doctor

NPI 1013913284 CMS profile 182667

1201 Seven Locks Rd, Ste 111, Rockville, MD 20854

Open in the dashboard

General payments

$4,054

225 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$224,226 paid to institutions, not to them · program years 2022–2024

Through program year 2025, Ira Berger of Rockville, MD is reported in the CMS Open Payments database as having received $4,054 across 225 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $224,226 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 87th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $395 15
2024 General $810 26
2023 General $345 16
2022 General $358 25
2021 General $753 55
2020 General $557 32
2019 General $837 56

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ira Berger
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Ira Berger were reported at $395. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Ira Berger Internal Medicine median Middle half National median
2019 $837 $159 $48–$570 $163
2020 $557 $119 $33–$402 $114
2021 $753 $135 $37–$521 $132
2022 $358 $141 $42–$496 $149
2023 $345 $149 $45–$519 $160
2024 $810 $154 $47–$537 $164
2025 $395 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $670 39 payments
  2. GlaxoSmithKline, LLC. $377 15 payments
  3. AbbVie, Inc. $367 40 payments
  4. Merck Sharp & Dohme Corporation $283 23 payments
  5. Novo Nordisk Inc $261 15 payments
  6. Pfizer Inc. $253 15 payments
  7. Mylan Specialty L.P. $245 14 payments
  8. Abbott Laboratories $172 3 payments
  9. Actelion Pharmaceuticals US, Inc. $134 3 payments
  10. Bioventus LLC $133 1 payment
  11. Other $1,157 57 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,951 223 payments
  2. Education $103 2 payments
Products named General payments · program years 2019–2025
  1. UBRELVY $326 35 payments
  2. Yupelri $200 12 payments
  3. Perforomist $200 12 payments
  4. Ozempic $185 11 payments
  5. AREXVY $169 4 payments
  6. TRELEGY ELLIPTA $154 8 payments
  7. SYMBICORT $145 10 payments
  8. BREZTRI $142 9 payments
  9. OPSUMIT $134 3 payments
  10. FreeStyle Libre 3 $134 1 payment
  11. Other $3,722 213 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 123 drugs

Part D claims

7,221

Median for Internal Medicine: 777

Drug cost

$602,015

Median for Internal Medicine: $73,373

Branded share of claims

19.2%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 151 $136,646
Eliquis Apixaban Brand 63 $72,149
Jardiance Empagliflozin Brand 27 $44,101
Januvia Sitagliptin Phosphate Brand 28 $39,701
Ozempic Semaglutide Brand 28 $39,413
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 59 $38,889
Nicotrol Ns Nicotine Brand 11 $22,425
Breo Ellipta Fluticasone/Vilanterol Brand 13 $12,996
Synthroid Levothyroxine Sodium Brand 148 $12,735
Xarelto Rivaroxaban Brand 12 $12,120

The 10 drugs with the highest cost, of 123 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 92 billing codes

Paid by Medicare

$378,841

Of which drugs: $39,242

Medicare patients

1,086

Average age 78

Services billed

10,290

535 women, 551 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 68%
Arthritis 43%
Ischemic heart disease 25%
Diabetes 22%
Cancer 19%
Osteoporosis 19%
Atrial fibrillation 17%
Chronic kidney disease 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 221 223 $18,095
Sarscov2 vac 50 mcg/0.5ml im 91322 Office 91 98 $14,915
Pcv20 vaccine im 90677 Office 20 20 $5,814

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AREXVY
  • GlaxoSmithKline, LLC. $129
$129 — —
OPSUMIT
  • Actelion Pharmaceuticals US, Inc. $95
$95 — —
UPTRAVI
  • Actelion Pharmaceuticals US, Inc. $39
$40 — —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $36
$36 — —
KRYSTEXXA
  • Amgen Inc. $31
$31 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

225 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record